MLchartDataset catalogue

vopikitug

Term · Oncology and biomedicine · MLC-T-ONC-017532

A monoclonal antibody against CD25 (IL-2R alpha), with potential antineoplastic activity. Upon administration, vopikitug targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells and prevent immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the interleukin (IL)-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.

Table 1. Record
IdentifierMLC-T-ONC-017532
FieldOncology and biomedicine
Synonymsanti-CD25 monoclonal antibody RG6292; T-regulatory cell-depleting antibody RO7296682; anti-CD25 monoclonal antibody RO7296682
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-017532",
  "term": "vopikitug",
  "field": "Oncology and biomedicine",
  "definition": "A monoclonal antibody against CD25 (IL-2R alpha), with potential antineoplastic activity. Upon administration, vopikitug targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells and prevent immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the interleukin (IL)-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.",
  "synonyms": [
    "anti-CD25 monoclonal antibody RG6292",
    "T-regulatory cell-depleting antibody RO7296682",
    "anti-CD25 monoclonal antibody RO7296682"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/vopikitug/"
}

Record 17,337 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.